Gsa Capital Partners LLP 9 Meters Biopharma, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $394,607 - $601,306	1,879,083 Added 400.48%	2,348,287 $505,000
Q2 2022 Aug 09, 2022	BUY	$0.26 - $0.64 $12,829 - $31,581	49,346 Added 11.75%	469,204 $122,000
Q1 2022 May 11, 2022	SELL	$0.52 - $1.0 $39,481 - $75,925	-75,925 Reduced 15.31%	419,858 $252,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $409,423 - $640,627	481,675 Added 3414.2%	495,783 $485,000
Q3 2021 Nov 12, 2021	BUY	$1.03 - $1.41 $14,531 - $19,892	14,108 New	14,108 $18,000
Q1 2021 May 10, 2021	SELL	$0.84 - $2.16 $18,984 - $48,816	-22,600 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$0.65 - $1.11 $14,690 - $25,086	22,600 New	22,600 $19,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.